The immunogenicity industry is changing rapidly; as successful breakthroughs by some and costly mistakes by others has left Pharma and Biotech companies struggling to avoid the patent cliff. Your success in the design and commercialization of new biologics depends on your ability to understand, predict and minimize the risk of immunogenic response. Adding to the challenge new U.S. and international regulatory guidelines for the monitoring and reporting of Immunogenicity.
Now in its 15th Year, IIRs Annual Immunogenicity for Biotherapeutics has proved itself as the largest and longest running event focusing solely on updates, new opportunities, and strategies to deal with increasing FDA scrutiny and take advantage of your industries growth opportunities; providing answers to your questions and a program driven by content YOU crafted.
With 80% of the program focusing on real life case studies; including success stories and mistakes made by leading biotech and pharmaceutical manufacturers.
Hear directly from the FDA and NIH and learn how Pharma is putting FDA guidance into practice.
Access global pharmaceutical experts to hear new perspectives and case studies on their experiences in dealing with pre-clinical, clinical and post clinical development of biologics.
Over 30 Never-Before-Heard Case Study Presentations
Deep Dive with Roundtables and 4 Pre-Conference Workshops
Conference Only : $1,795-$2,395
Conference Plus Workshop : $2,095-$2,695
Super Pass (access to main conference for Immuno Event and co-located 10th Annual Bioassays and Bioanalytical Method Development conference only) : $2,695-$3,295
Super Pass + (access to both co-located conferences and all workshops) : $3,295-$3,895
From: October 20, 2014 08:15
To: October 22, 2014 16:00
Omni Parker House, 60 School St, 02108, Boston, United States